^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
CTX131
i
Other names: CTX131, CTX-131, CTX 131
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
CRISPR Therap
Drug class:
CD70-targeted CAR-T immunotherapy
Related drugs:
4ms
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies (clinicaltrials.gov)
P1/2, N=290, Recruiting, CRISPR Therapeutics | Not yet recruiting --> Recruiting
Enrollment open
|
CTX131
5ms
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies (clinicaltrials.gov)
P1/2, N=290, Not yet recruiting, CRISPR Therapeutics
New P1/2 trial
|
CTX131
8ms
CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma. (PubMed, Cancer Discov)
Finally, we report on a next-generation CAR T construct, CTX131, in which synergistic potency edits to CTX130 confer improved expansion and efficacy in preclinical studies. Although the role of CAR T cells is well established in hematologic malignancies, the clinical experience in solid tumors has been disappointing. This clinical trial demonstrates the first complete response in a patient with RCC, reinforcing the potential benefit of CAR T cells in the treatment of solid tumors.
Journal • CAR T-Cell Therapy • Metastases
|
CD70 (CD70 Molecule)
|
CTX130 • CTX131
Share via
